Emergent BioSolutions Inc. (NYSE:EBS) Short Interest Update

Emergent BioSolutions Inc. (NYSE:EBS) was the recipient of a large decline in short interest during the month of October. As of October 15th, there was short interest totalling 7,790,000 shares, a decline of 5.3% from the September 30th total of 8,230,000 shares. Currently, 15.0% of the company’s shares are sold short. Based on an average trading volume of 2,780,000 shares, the days-to-cover ratio is presently 2.8 days.

Analysts Set New Price Targets

A number of brokerages have recently issued reports on EBS. Rodman & Renshaw restated a “buy” rating and set a $16.00 price target on shares of Emergent BioSolutions in a report on Friday, September 13th. Benchmark reissued a “buy” rating and set a $8.00 target price on shares of Emergent BioSolutions in a research note on Friday, August 16th.

Emergent BioSolutions Trading Down 3.7 %

NYSE EBS traded down $0.36 during trading hours on Thursday, reaching $9.24. The company had a trading volume of 494,406 shares, compared to its average volume of 3,443,478. Emergent BioSolutions has a 1-year low of $1.42 and a 1-year high of $15.10. The stock has a market capitalization of $484.19 million, a P/E ratio of -0.88 and a beta of 1.59. The stock has a 50-day moving average of $8.35 and a 200 day moving average of $7.40. The company has a current ratio of 1.06, a quick ratio of 0.54 and a debt-to-equity ratio of 1.16.

Emergent BioSolutions (NYSE:EBS) last issued its quarterly earnings data on Tuesday, August 6th. The biopharmaceutical company reported ($2.32) EPS for the quarter, missing the consensus estimate of ($0.97) by ($1.35). The company had revenue of $254.70 million during the quarter, compared to analyst estimates of $199.47 million. Emergent BioSolutions had a negative return on equity of 34.38% and a negative net margin of 53.26%. During the same quarter in the prior year, the company posted ($1.06) earnings per share. As a group, research analysts anticipate that Emergent BioSolutions will post -1.3 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Emergent BioSolutions

Hedge funds and other institutional investors have recently bought and sold shares of the company. PFG Investments LLC acquired a new stake in shares of Emergent BioSolutions during the third quarter worth about $228,000. Assenagon Asset Management S.A. increased its stake in Emergent BioSolutions by 74.5% during the 3rd quarter. Assenagon Asset Management S.A. now owns 741,552 shares of the biopharmaceutical company’s stock worth $6,192,000 after buying an additional 316,700 shares during the period. SeaCrest Wealth Management LLC lifted its holdings in Emergent BioSolutions by 3.2% during the 3rd quarter. SeaCrest Wealth Management LLC now owns 118,700 shares of the biopharmaceutical company’s stock worth $991,000 after buying an additional 3,705 shares in the last quarter. SG Americas Securities LLC boosted its position in Emergent BioSolutions by 250.1% in the 3rd quarter. SG Americas Securities LLC now owns 60,724 shares of the biopharmaceutical company’s stock valued at $507,000 after buying an additional 43,378 shares during the period. Finally, Truist Financial Corp grew its stake in shares of Emergent BioSolutions by 12.3% in the second quarter. Truist Financial Corp now owns 131,526 shares of the biopharmaceutical company’s stock worth $897,000 after acquiring an additional 14,360 shares in the last quarter. 78.40% of the stock is currently owned by hedge funds and other institutional investors.

Emergent BioSolutions Company Profile

Emergent BioSolutions Inc, a life sciences company, provides preparedness and response solutions for accidental, deliberate, and naturally occurring public health threats in the United States. The company offers NARCAN Nasal Spray for the emergency treatment of known or suspected opioid overdose; Vaxchora vaccine for the prevention of cholera; Vivotif vaccine for oral administration for the prevention of typhoid fever; Anthrasil for the treatment of inhalational anthrax; BioThrax, an anthrax vaccine; CYFENDUS for post-exposure prophylaxis of disease following suspected or confirmed exposure to Bacillus anthracis; and Raxibacumab injection for the treatment and prophylaxis of inhalational anthrax.